Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
2025 · 4th Quarter (Oct 1 - Dec 31)
SAREPTA THERAPEUTICS
Filed by MICHAEL BEST STRATEGIES LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $110,000.00
- Expenses
- Not reported
- Registrant
- MICHAEL BEST STRATEGIES LLC
- Client
- SAREPTA THERAPEUTICS
- Filing UUID
- 6e4c8043-70a9-464f-8717-a8483c70166b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.